Systems and methods to process electronic images to predict biallelic mutations
A computer-implemented method may diagnose invasive lobular carcinoma. The method may include receiving one or more digital images into a digital storage device, applying a trained machine learning module to detect a presence or absence of CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation from the received one or more digital images, and determining whether the patient has invasive lobular carcinoma using the detected presence or absence of the CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation as ground truth. The one or more digital images may include images of breast tissue of a patient.
1. A computer-implemented method for diagnosing invasive lobular carcinoma, the method comprising:
receiving one or more digital images into a digital storage device, the one or more digital images including images of breast tissue of a patient;
applying a trained machine learning module to detect a presence or absence of CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation from the received one or more digital images, the trained machine learning module having been trained using labels of one or more training digital images, wherein the labels correspond to a presence or absence of CDH1; and
determining whether the patient has invasive lobular carcinoma using the detected presence or absence of the CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation as ground truth, the trained machine learning module having been trained using a plurality of digital images of breast tissue from a plurality of patients and associated mutation data, the associated mutation data comprising integrated mutation profiling of actionable cancer targets (MSK-IMPACT) targeted sequencing data.
2. The computer-implemented method of claim 1 , wherein the trained machine learning module was trained using a 10-fold cross-validation method.
3. The computer-implemented method of claim 1 , further including applying the trained machine learning module to predict a lobular phenotype.
4. The computer-implemented method of claim 1 , further comprising:
receiving supplemental patient information, wherein determining whether the patient has invasive lobular carcinoma is based on the received supplemental patient information.
5. The computer-implemented method of claim 4 , wherein the supplemental patient information includes patient demographics, medical history, cancer treatment history, family history, past biopsy or cytology information, additional test results, radiology imaging, genomic test results, molecular test results, historical pathology specimen images, and/or location of the breast tissue.
6. The computer-implemented method of claim 1 , further comprising outputting the determination on an electronic display.
7. A system for diagnosing invasive lobular carcinoma, comprising:
at least one memory storing instructions; and
at least one processor configured to execute the instructions to perform operations comprising:
receiving one or more digital images into a digital storage device, the one or more digital images including images of breast tissue of a patient;
applying a trained machine learning module to detect a presence or absence of CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation from the received one or more digital images, the trained machine learning module having been trained using labels of one or more training digital images, wherein the labels correspond to a presence or absence of CDH1; and
determining whether the patient has invasive lobular carcinoma using the detected presence or absence of the CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation as ground truth, the trained machine learning module having been trained using a plurality of digital images of breast tissue from a plurality of patients and associated mutation data, the associated mutation data comprising integrated mutation profiling of actionable cancer targets (MSK-IMPACT) targeted sequencing data.
8. The system of claim 7 , wherein the trained machine learning module was trained using a 10-fold cross-validation method.
9. The system of claim 7 , wherein the operations further comprise applying the trained machine learning module to predict a lobular phenotype.
10. The system of claim 7 , wherein the operations further comprise:
receiving supplemental patient information, wherein determining whether the patient has invasive lobular carcinoma is based on the received supplemental patient information.
11. The system of claim 10 , wherein the supplemental patient information includes patient demographics, medical history, cancer treatment history, family history, past biopsy or cytology information, additional test results, radiology imaging, genomic test results, molecular test results, historical pathology specimen images, and/or location of the breast tissue.
12. The system of claim 7 , wherein the operations further comprise outputting the determination on an electronic display.
13. A non-transitory computer-readable medium storing instructions that, when executed by a processor, cause the processor to perform operations for diagnosing invasive lobular carcinoma, the operations comprising:
receiving one or more digital images into a digital storage device, the one or more digital images including images of breast tissue of a patient;
applying a trained machine learning module to detect a presence or absence of CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation from the received one or more digital images, the trained machine learning module having been trained using labels of one or more training digital images, wherein the labels correspond to a presence or absence of CDH1; and
determining whether the patient has invasive lobular carcinoma using the detected presence or absence of the CDH1 biallelic genetic inactivation and/or CDH1 biallelic mutation as ground truth, the trained machine learning module having been trained using a plurality of digital images of breast tissue from a plurality of patients and associated mutation data, the associated mutation data comprising integrated mutation profiling of actionable cancer targets (MSK-IMPACT) targeted sequencing data.
14. The computer-readable medium of claim 13 , wherein the operations further comprise receiving supplemental patient information, wherein determining whether the patient has invasive lobular carcinoma is based on the received supplemental patient information.